If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
210
results.
Updated on
21/02/2026 [06:51:00]
Results 150 to 175 of 210
Absstract of: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Absstract of: WO2024200823A1
The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain capable of specifically binding to a target expressed on activated immune cells surface and one or several mRNA molecule(s) encoding an activity-enhancing protein of said activated immune cells, and to uses thereof.
Absstract of: AU2024254671A1
The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.
Absstract of: CN120826370A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular of Na; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of Na, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing compositions/solutions 1 and 2 and placing the mixture under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating the formed nanoparticles. According to the invention, the first composition/solution 1 and the second composition/solution 2 each consist of said source and an alkaline phosphate buffer (PBS). The invention also relates to the nanoparticles thus obtained and to compositions containing these nanoparticles.
Absstract of: CN120826371A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular a source of ions of K; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of K, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing the composition/solutions 1 and 2 and standing under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating said nanoparticles formed. According to the invention, both the first composition/solution 1 and the second composition/solution 2 consist of said source and an aqueous buffer. The invention also relates to colloidal suspensions of the resulting nanoparticles, and to pharmaceutical compositions comprising said nanoparticles.
Absstract of: CN121489902A
本发明涉及生物技术领域，具体公开了靶向消融脂肪细胞的噬菌体纳米颗粒及其制备方法和应用，所述噬菌体纳米颗粒包括经基因工程改造的M13噬菌体，其表面展示有脂肪细胞靶向肽ATS；包载于噬菌体纳米颗粒内部的功能分子姜黄素；以及用于稳定负载的功能聚合物P4VP外壳，本发明通过噬菌体纳米材料携带功能分子姜黄素，在脂肪细胞局部实现高效杀伤，能够精准、高效、安全且微创地消除体内多余脂肪细胞的治疗方法，解决了现有肥胖治疗手段的诸多痛点，治疗方案操作相对简便，对医生技术的依赖性低于复杂的吸脂手术，更易于在临床推广和应用。
Absstract of: CN121495950A
本发明属于生物医药技术领域，提供一种猪急性腹泻综合征冠状病毒的S蛋白祖先序列AS mRNA，通过系统发育分析，构建SADS‑CoV Spike蛋白的祖先序列，该序列不仅针对现有的病毒，还针对病毒的进化谱系；利用该序列设计的从针对单一病原体的目标性防御转变为对病毒进化轨迹的主动干预；制备的AS mRNA疫苗对动物的饲养安全和人畜共患疾病的防控具有重要意义。
Absstract of: CN121489899A
本发明公开了一种脂质体纳米颗粒体外释放介质及体外释放测试方法，脂质体纳米颗粒体外释放介质包括如下组分：缓冲液和脂质；其中，脂质为DOPE和至少DOPS、POPS、DOPC、DSPC、Egg PC、Lyso PC、DPPC、DPPE、DMPE、POPE、DOPG、DGPG中的一种或多种。本发明中的脂质体纳米颗粒体外释放介质在体外模拟机体内环境，通过检测核酸、多肽、抗体含量，绘制体外释放曲线，对脂质纳米颗粒的处方开发及质量研究具有重要意义。
Absstract of: CN121489904A
本发明属于微纳米马达领域，提供一种细胞膜伪装光驱动纳米马达及其制备方法和应用。纳米马达Cu2‑x Se‑PMO由近红外光响应的硒化铜Cu2‑xSe纳米颗粒以及周期性介孔有机硅PMO纳米球组成，将载药纳米马达和细胞膜纳米囊泡混合共同通过微孔滤膜获得细胞膜伪装的纳米马达CM@Cu2‑x Se‑PMO。纳米马达能够主动寻找目标疾病部位，本发明的细胞膜伪装光驱动纳米马达能提高药物运输的效率和靶向性，本发明的制备方法具有装载率高，靶向性高，成本低等特点。
Absstract of: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Absstract of: MX2025013363A
The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:
Absstract of: CN121490050A
本发明公开了一种基于传统中药复方的抗宫颈癌纳米靶向片剂及其制备方法，所述纳米靶向片剂由以下重量份的原料组成：蜈蚣、金钱白花蛇、海龙、全蝎、露蜂房、水蛭、土鳖虫、乳香、没药、蒲公英、香附、柴胡、枳壳、黄柏、当归、郁金、茯苓、白术、白芍、合欢皮、山药、白花蛇舌草和夏枯草。本发明将中药材通过现代提取技术最大化保留并富集活性成分，确保最大限度保留原方疗效，而通过叶酸受体、CD44受体及pH敏感三重靶向机制，使药物富集于宫颈癌组织，提高局部药物浓度，降低系统毒性，实现精准靶向递送。
Absstract of: CN121489900A
本申请涉及一种靶向恶性肿瘤的藤黄酸制剂的制备与应用。采用内核‑中层‑外壳三层结构：内核为藤黄酸‑黑磷量子点复合物，兼具化学治疗与光热治疗功能；中层为冷冻化NK92 MI细胞来源的纳米囊泡，提供天然免疫靶向与杀伤能力；外壳为透明质酸螯合物，实现主动靶向与pH/光热响应型药物控制释放。其制备方法核心在于采用同轴电喷射技术，将三层物料一步成型，工艺高效且制剂稳定性好。该制剂能够实现光热‑化学‑免疫三重协同治疗，并同时具备近红外荧光与光声多模成像功能，有效解决了传统化疗靶向性差、毒副作用大及缺乏实时监控的难题，在实体瘤的精准治疗与诊断中展现出显著优势和应用潜力。
Absstract of: CN121490096A
本发明公开了一种超小丹酚酸B‑铕金属多酚网络，其由丹酚酸B、EuCl3·6H2O和牛血清白蛋白自组装而成。本发明还公开了所述超小丹酚酸B‑铕金属多酚网络的制备方法及其在制备用于治疗肾结石的药物中的应用。本发明的超小丹酚酸B‑铕金属多酚网络SAB‑Eu@BSA兼具结晶抑制、调节氧化应激稳态和肾可清除特性，在草酸钙肾病治疗方面显示出巨大的潜力。
Absstract of: CN121489903A
本发明属于生物医药技术领域，具体涉及M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统及其制备方法和应用。M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统由搭载治疗药物的ROS响应纳米颗粒和包裹在所述ROS响应纳米颗粒外的M2巨噬细胞膜组成。本发明所提供的M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统生物相容性优异，具有免疫逃逸、精准靶向、清除细胞内ROS、抑制炎症损伤和细胞凋亡等功能，为动脉粥样硬化提供了一种兼具靶向递送、智能释药及多维度调控的仿生纳米递送系统。
Absstract of: CN121495105A
本发明公开了一种二硒键链接硝基咪唑与聚乙二醇的两亲性分子及其应用，属于医药技术领域。本发明提供一种通过二硒键链接硝基咪唑与聚乙二醇的两亲性分子MNZ‑Se2‑PEG，结构式如(Ⅰ)所示。该两亲性分子通过自组装可以包载化疗药物形成递药系统。制备的递药系统具有生理条件下可保持结构稳定、可通过辐射响应性释放药物和放疗增敏等优势，起到放化疗协同治疗作用；而且制备的递药系统生物安全性好。本发明为实现放化疗的协同增效提供了一个可靠的载体平台，具备优异的化疗药物递送系统开发潜力。
Absstract of: CN121489901A
本发明属于药物制剂新剂型与靶向递送技术领域，涉及一种基于代谢酶相关的淫羊藿素前药或其药学上可接受的盐的纳米粒与菊粉凝胶的复合制剂及其制备方法与应用。本发明将淫羊藿素氨基甲酸酯前药或其药学上可接受的盐制备成PLGA纳米粒以提高其溶解度，并将该纳米粒嵌入菊粉凝胶中，构建了一种口服结肠靶向递药系统。为解决难溶性药物递送及炎症性肠病及其并发症的高效治疗提供了新的策略与选择。
Absstract of: CN121494840A
本发明属于抗菌材料技术领域，特别涉及一种两性离子型的光敏剂材料、纳米粒子及其制备方法和应用。本发明两性离子型的光敏剂材料的结构式为：；其中，x取3‑5之间的任意整数；R1、R2基团均为：。本发明基于磺酸化的两性离子型光敏剂材料具有优异亲水性和生物活性，可在低剂量下完成高效杀菌作用，对小鼠活体伤口感染具有高效的治愈性，因此可用于制备治疗伤口感染的药物，解决现有技术中聚集导致荧光猝灭效应，以及聚集导致ROS产率下降所导致的抗菌治疗效果不佳的问题。
Absstract of: CN121490077A
本发明的目的在于提供一种“光热联合化疗”治疗肿瘤的有机物‑有机物纳米复合物的制备方法及应用，属于抗肿瘤药物技术领域，本发明采用溶剂交换法制备了尺寸均一的1,4‑苯二异硫氰酸酯‑吲哚菁绿纳米复合物。得到的PDITC@ICG纳米复合物可以在近红外激光的激发下由光能转换为热能致局部升温导致癌细胞凋亡，并且与化疗之间起到相互增效的作用，实现了协同治疗肿瘤的效果。该种治疗方法具有明显的抑制肿瘤生长甚至达到肿瘤完全消失的效果。该体系具有良好的生物相容性和生物安全性，可以为临床三阴性乳腺癌患者提供一种具有时空精确性且诊疗一体化的潜在治疗方案。
Absstract of: CN121489871A
本发明属于药物制剂领域，提供了一种用于难溶性药物肺部给药的辅料体系及其制备方法。本发明采用脂质包覆难溶性药物纳米晶核壳颗粒与三元脂质分散中间体协同设计，通过抗溶剂沉淀原位包覆与高压微射流细化技术，将尼达尼布纳米晶外表面包覆由二棕榈酰‑sn‑甘油‑3‑磷酰胆碱、胆固醇和丙二醇辛酸酯构成的脂质壳层，形成质量中值粒径D50值为150‑250nm、体积分布D90值为≤400nm的核壳颗粒。本发明实现了高载药量、低黏度可雾化、优选肺部沉积分布和长期粒径稳定性，有效缓解了难溶性药物肺部给药中高固含与流变性能、低刺激性与胶体稳定性、雾化效率与核壳结构完整性之间的矛盾，具有广泛的临床应用价值。
Absstract of: CN121495116A
本发明涉及高分子药物载体技术领域，具体是一种聚氨基酸纳米载体、聚氨基酸纳米粒子及其制备方法。本发明提供的聚氨基酸纳米粒子能够通过清除活性氧来抑制M2巨噬细胞的产生，并通过释放免疫刺激剂促进巨噬细胞的M1型极化用于骨肉瘤的免疫治疗。此外，聚氨基酸纳米粒子中的阿仑膦酸成分在提高肿瘤靶向性的基础上，也能够抑制破骨细胞活性进而减轻骨质破坏。试验表明，本发明提供的聚氨基酸纳米粒子静脉注射到荷骨肉瘤小鼠体内后明显抑制了原位骨肉瘤的进展。因此，本发明提供的巨噬细胞极化可调控的聚氨基酸纳米粒子启动的免疫疗法为临床骨肉瘤治疗提供了一种有前途的替代方案。
Absstract of: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Absstract of: AU2024209240A1
The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to processes for the preparation of such compositions, pharmaceutical dosage forms comprising or made from such compositions, and uses of such pharmaceutical dosage forms for medical purposes.
Absstract of: CN120548194A
The present disclosure relates to hMPV F, PIV3F, and PIV1F protein mutants, nucleic acids or vectors encoding the hMPV F, PIV3F, and PIV1F protein mutants, compositions comprising the hMPV F, PIV3F, and PIV1F protein mutants or nucleic acids, and uses of the hMPV F, PIV3F, and PIV1F protein mutants, nucleic acids or vectors, and compositions.
Nº publicación: JP2026505025A 10/02/2026
Applicant:
ザメソディストホスピタル
Absstract of: CN120813699A
Provided herein are a method of preparing a circular RNA, a method of isolating a circular RNA, and a composition comprising a circular RNA.
BOPI
Electronic site
